Latest news with #BMJ
Scottish Sun
11 hours ago
- Health
- Scottish Sun
Urgent warning over drug taken by millions – as AstraZeneca accused of ‘misreporting' safety data
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) MEDICS have raised concerns over a drug taken by millions to prevent heart attacks and strokes, claiming key safety data was "misreported" by its manufacturer AstraZeneca. Anti-clotting pill ticagrelor has been available on the NHS in 2011, after trials appeared to show it could prevent one in five deaths after a heart attack. Sign up for Scottish Sun newsletter Sign up 1 A BMJ investigation has raised concerns over clinical trials that spurred on the approval of ticagrelor, sold as Brilique But an investigation published in the BMJ cast doubt "over the integrity of the clinical trials that underpinned its approval". Ticagrelor is an antiplatelet medicine that prevents blood cells from sticking together and forming dangerous clots. The twice-daily pill is prescribed to patients with acute coronary syndrome who are at greater risk of blood clots due to a history of heart attack, angina or stroke - often in combination with a low dose of aspirin. In the UK, the drug is prescribed around 45,000 times per month on the NHS. Now, experts claim to have uncovered "evidence of serious misreporting" in two clinical trials that were pivotal to the drug's approval in the UK and US. These findings raise "doubts over the approval and decade long use of ticagrelor", sold as Brilique in the UK, the report authors wrote in the BMJ. In response, an AstraZeneca spokesperson told Sun Health: 'We are confident in the integrity of the trials and its evidence in support for Brilique.' Two AstraZeneca studies, known as ONSET/OFFSET and RESPOND, were published in the leading journal Circulation, reporting the drug's effects on platelet function. The ONSET/OFFSET trial involved 123 patients and found that ticagrelor was faster and better at preventing clots than a competitor drug. Similar results were published in RESPOND, which involved 98 patients. Early warning sign of heart attack you may notice in bed But the report authors claimed claimed 'primary endpoint' results in the two key trials - which were pivotal in determining the treatment's effectiveness - were inaccurately reported in Circulation. "We found evidence that the trials were inaccurately reported," they said. "In one instance, AstraZeneca's trial failed to show statistical significance, but was published in a leading cardiology journal as significant." It also said around a quarter of the readings from machines used in the trials were not included in the data sets, the US medicine's regulator, the Food and Drug Administration (FDA) used to approve the drug. In order for ticagrelor to get approved, clinical trials had to prove that it was a better drug than competitors in a phase 3 trial. After phase 3 and drug approval, the FDA and MHRA in the UK, continues monitoring it in phase 4 trials, to see if there are any additional problems with the drug. But the BMJ analysis of two phase 2 trial results found there were instances of patients whose blood "platelet aggregation dramatically increased". This is when blood cells stick together to form clumps, which can lead to blood clots - exactly what the drug aims to prevent. Key facts about ticagrelor Ticagrelor is an antiplatelet medicine that prevents platelets - a type of blood cell - from sticking together and forming a dangerous blood clot. Taking ticagrelor can help prevent blood clots if you have an increased risk of having them because you: Have had a heart attack Have unstable angina Have had a stroke or a transient ischaemic stroke (TIA, or mini-stroke) Ticagrelor is only available on prescription. You'll usually take ticagrelor twice a day and it's often prescribed together with low-dose aspirin at the start of treatment. The main side effects of ticagrelor are getting out of breath and bleeding more easily than normal. You may have nosebleeds, heavier periods, bleeding gums and bruising. According to medicines watchdog the National Institute for Health and Care Excellence (NICE), patients are advised to take the drug twice a day at 90mg for around a year after a heart attack. A lower dose of 60mg, may then be prescribed by doctors for up to a further three years. It may also be taken by those who have suffered a minor stroke or a transient ischaemic attack at 90mg alongside aspirin. Sources: NHS, NICE This is "an improbable effect for an anti-platelet drug" and "suggests an incorrect laboratory reading", the BMJ said. Assessing the readings from platelet machines used at the two trial sites, led by cardiologist Dr Paul Gurbel, investigators also found more than 60 of the 282 readings were not included in datasets submitted to the FDA. "The platelet activity levels not entered were significantly higher than those used in the Circulation papers and FDA datasets," they claimed. "It is unclear whose blood was sampled, and why those measurements did not contribute to data in either trial." The report authors conducted their investigation through interviews with trial investigators and platelet experts and access to the underlying trial data submitted to regulators. They also said that principal investigators involved in ticagrelor trials "were unreachable or declined to be interviewed". "The findings raise even deeper questions over the approval and decade long use of the drug," the authors claimed. Dr Victor Serebruany, an expert in cardiovascular pharmacology at Johns Hopkins University in Maryland, who has been critical of the drug for over a decade said: "It's been obvious for years that there is something wrong with the data. "That the FDA's leadership could look past all these problems- on top of the many problems their own reviewers identified and are now being discovered by The BMJ - is unconscionable. "We all need to know how and why that happened. "If doctors had known what happened in these trials, they would never have started using ticagrelor." But a spokesperson for the Sinai Center for Thrombosis Research and Drug Development, which Dr Gurbel leads, told MailOnline: "Any allegations of any research misconduct in the two studies are baseless and erroneous." Sun Health has also contacted Circulation for comment. The journal did not respond to the BMJ.
The Irish Sun
11 hours ago
- Health
- The Irish Sun
Urgent warning over drug taken by millions – as AstraZeneca accused of ‘misreporting' safety data
MEDICS have raised concerns over a drug taken by millions to prevent heart attacks and strokes, claiming key safety data was "misreported" by its manufacturer AstraZeneca. Anti-clotting pill ticagrelor has been available on the NHS in 2011, after trials appeared to show it could prevent one in five deaths after a heart attack. 1 A BMJ investigation has raised concerns over clinical trials that spurred on the approval of ticagrelor, sold as Brilique But Ticagrelor is an antiplatelet medicine that prevents blood cells from sticking together and The twice-daily pill is prescribed to patients with acute coronary syndrome who are at greater risk of blood clots due to a history of In the UK, the drug is prescribed around 45,000 times per month on the NHS. Read more on medication Now, experts claim to have uncovered "evidence of serious misreporting" in two clinical trials that were pivotal to the drug's approval in the UK and US. These findings raise "doubts over the approval and decade long use of ticagrelor", sold as Brilique in the UK, the report authors wrote in the BMJ . In response, an AstraZeneca spokesperson told Sun Health: 'We are confident in the integrity of the trials and its evidence in support for Brilique.' Two AstraZeneca studies, known as ONSET/OFFSET and RESPOND, were published in the leading journal Circulation , reporting the drug's effects on platelet function. Most read in Uncategorized The ONSET/OFFSET trial involved 123 patients and found that ticagrelor was faster and better at preventing clots than a competitor drug. Similar results were published in RESPOND, which involved 98 patients. Early warning sign of heart attack you may notice in bed But the report authors claimed claimed 'primary endpoint' results in the two key trials - which were pivotal in determining the treatment's effectiveness - were inaccurately reported in Circulation . "We found evidence that the trials were inaccurately reported," they said. "In one instance, AstraZeneca's trial failed to show statistical significance, but was published in a leading cardiology journal as significant." It also said around a quarter of the readings from machines used in the trials were not included in the data sets, the US medicine's regulator, the Food and Drug Administration (FDA) used to approve the drug. In order for ticagrelor to get approved, clinical trials had to prove that it was a better drug than competitors in a phase 3 trial. After phase 3 and drug approval, the FDA and MHRA in the UK, continues monitoring it in phase 4 trials, to see if there are any additional problems with the drug. But the BMJ analysis of two phase 2 trial results found there were instances of patients whose blood "platelet aggregation dramatically increased". This is when blood cells stick together to form clumps, which can lead to blood clots - exactly what the drug aims to prevent. Key facts about ticagrelor Ticagrelor is an antiplatelet medicine that prevents platelets - a type of blood cell - from sticking together and forming a dangerous blood clot. Taking ticagrelor can help prevent blood clots if you have an increased risk of having them because you: Have had a heart attack Have unstable angina Have had a stroke or a transient ischaemic stroke (TIA, or mini-stroke) Ticagrelor is only available on prescription. You'll usually take ticagrelor twice a day and it's often prescribed together with low-dose aspirin at the start of treatment. The main side effects of ticagrelor are getting out of breath and bleeding more easily than normal. You may have nosebleeds, heavier periods, bleeding gums and bruising. According to medicines watchdog the National Institute for Health and Care Excellence (NICE), patients are advised to take the drug twice a day at 90mg for around a year after a heart attack. A lower dose of 60mg, may then be prescribed by doctors for up to a further three years. It may also be taken by those who have suffered a minor stroke or a transient ischaemic attack at 90mg alongside aspirin. Sources: NHS, NICE This is "an improbable effect for an anti-platelet drug" and "suggests an incorrect laboratory reading", the BMJ said. Assessing the readings from platelet machines used at the two trial sites, led by cardiologist Dr Paul Gurbel, investigators also found more than 60 of the 282 readings were not included in datasets submitted to the FDA. "The platelet activity levels not entered were significantly higher than those used in the Circulation papers and FDA datasets," they claimed. "It is unclear whose blood was sampled, and why those measurements did not contribute to data in either trial." The report authors conducted their investigation through interviews with trial investigators and platelet experts and access to the underlying trial data submitted to regulators. They also said that principal investigators involved in ticagrelor trials "were unreachable or declined to be interviewed". "The findings raise even deeper questions over the approval and decade long use of the drug," the authors claimed. Dr Victor Serebruany, an expert in cardiovascular pharmacology at Johns Hopkins University in Maryland, who has been critical of the drug for over a decade said: "It's been obvious for years that there is something wrong with the data. "That the FDA's leadership could look past all these problems- on top of the many problems their own reviewers identified and are now being discovered by The BMJ - is unconscionable. "We all need to know how and why that happened. "If doctors had known what happened in these trials, they would never have started using ticagrelor." But a spokesperson for the Sinai Center for Thrombosis Research and Drug Development, which Dr Gurbel leads, told Sun Health has also contacted Circulation for comment. The journal did not respond to the BMJ . How to reduce your risk of heart attacks and stroke You can reduce your risk of heart attack and stroke with many of the same methods. Heart attacks and strokes, although affecting different organs of the body, are both what we call cardiovascular events. Both arise from similar underlying conditions, such as atherosclerosis —a buildup of fatty deposits in the arteries. According to the American Heart Association, the risk factors for heart attacks and strokes are largely the same: high blood pressure, high cholesterol, smoking, obesity, physical inactivity and diabetes. Therefore, addressing these risk factors can simultaneously reduce the risk of both conditions. Here are ways you can prevent the two: Healthy diet More fruit and veg: The DASH, which emphasises fruit, vegetables, whole grains and lean proteins, has been shown to reduce blood pressure and improve heart health. Less fats: Too much saturated and trans fats can raise cholesterol levels and increase the risk of atherosclerosis. Go for healthier fats like those found in olive oil, nuts, and avocados. Limit salt: High salt intake is linked to high blood pressure, a major risk factor for both heart attack and stroke. The NHS recommends no more than 6g of salt per day for adults. Fibre: Foods high in soluble fibre, such as oats and beans, can help lower cholesterol levels. Exercise Walking, running, cycling, swimming - whatever you like, do it! Aerobic exercise can strengthen the heart and improve circulation. The NHS advises at least 150 minutes of moderate-intensity aerobic activity or 75 minutes of vigorous-intensity activity each week. Strength training exercises can help control weight, improve cholesterol levels, and reduce blood pressure. It is recommended twice a week by the NHS. Manage blood pressure Healthy diet and exercise can help keep your blood pressure in check. But it is worth monitoring it yourself after the age of 40, at least, when the NHS invites adults for a check-up every five years. High blood pressure often has no symptoms but significantly increases the risk of heart attack and stroke. Quit smoking One of the best ways to quit smoking is to use resources provided by NHS Smokefree. Support groups, medications, and other tools to help quit smoking such as vapes could be what you need to kick the habit for good - and it's free. Limit booze Excessive alcohol consumption can increase blood pressure and contribute to weight gain, which can snowball and become a heart health risk. The NHS recommends not regularly drinking more than 14 units of alcohol per week.
The Sun
11 hours ago
- Health
- The Sun
Urgent warning over drug taken by millions – as AstraZeneca accused of ‘misreporting' safety data
MEDICS have raised concerns over a drug taken by millions to prevent heart attacks and strokes, claiming key safety data was "misreported" by its manufacturer AstraZeneca. Anti-clotting pill ticagrelor has been available on the NHS in 2011, after trials appeared to show it could prevent one in five deaths after a heart attack. But an investigation published in the BMJ cast doubt "over the integrity of the clinical trials that underpinned its approval". Ticagrelor is an antiplatelet medicine that prevents blood cells from sticking together and forming dangerous clots. The twice-daily pill is prescribed to patients with acute coronary syndrome who are at greater risk of blood clots due to a history of heart attack, angina or stroke - often in combination with a low dose of aspirin. In the UK, the drug is prescribed around 45,000 times per month on the NHS. Now, experts claim to have uncovered "evidence of serious misreporting" in two clinical trials that were pivotal to the drug's approval in the UK and US. These findings raise "doubts over the approval and decade long use of ticagrelor", sold as Brilique in the UK, the report authors wrote in the BMJ. In response, an AstraZeneca spokesperson told Sun Health: 'We are confident in the integrity of the trials and its evidence in support for Brilique.' Two AstraZeneca studies, known as ONSET/OFFSET and RESPOND, were published in the leading journal Circulation, reporting the drug's effects on platelet function. The ONSET/OFFSET trial involved 123 patients and found that ticagrelor was faster and better at preventing clots than a competitor drug. Similar results were published in RESPOND, which involved 98 patients. Early warning sign of heart attack you may notice in bed But the report authors claimed claimed 'primary endpoint' results in the two key trials - which were pivotal in determining the treatment's effectiveness - were inaccurately reported in Circulation. "We found evidence that the trials were inaccurately reported," they said. "In one instance, AstraZeneca's trial failed to show statistical significance, but was published in a leading cardiology journal as significant." It also said around a quarter of the readings from machines used in the trials were not included in the data sets, the US medicine's regulator, the Food and Drug Administration (FDA) used to approve the drug. In order for ticagrelor to get approved, clinical trials had to prove that it was a better drug than competitors in a phase 3 trial. After phase 3 and drug approval, the FDA and MHRA in the UK, continues monitoring it in phase 4 trials, to see if there are any additional problems with the drug. But the BMJ analysis of two phase 2 trial results found there were instances of patients whose blood "platelet aggregation dramatically increased". This is when blood cells stick together to form clumps, which can lead to blood clots - exactly what the drug aims to prevent. Key facts about ticagrelor Ticagrelor is an antiplatelet medicine that prevents platelets - a type of blood cell - from sticking together and forming a dangerous blood clot. Taking ticagrelor can help prevent blood clots if you have an increased risk of having them because you: Have had a heart attack Have unstable angina Have had a stroke or a transient ischaemic stroke (TIA, or mini-stroke) Ticagrelor is only available on prescription. You'll usually take ticagrelor twice a day and it's often prescribed together with low-dose aspirin at the start of treatment. The main side effects of ticagrelor are getting out of breath and bleeding more easily than normal. You may have nosebleeds, heavier periods, bleeding gums and bruising. According to medicines watchdog the National Institute for Health and Care Excellence (NICE), patients are advised to take the drug twice a day at 90mg for around a year after a heart attack. A lower dose of 60mg, may then be prescribed by doctors for up to a further three years. It may also be taken by those who have suffered a minor stroke or a transient ischaemic attack at 90mg alongside aspirin. Sources: NHS, NICE This is "an improbable effect for an anti-platelet drug" and "suggests an incorrect laboratory reading", the BMJ said. Assessing the readings from platelet machines used at the two trial sites, led by cardiologist Dr Paul Gurbel, investigators also found more than 60 of the 282 readings were not included in datasets submitted to the FDA. "The platelet activity levels not entered were significantly higher than those used in the Circulation papers and FDA datasets," they claimed. "It is unclear whose blood was sampled, and why those measurements did not contribute to data in either trial." The report authors conducted their investigation through interviews with trial investigators and platelet experts and access to the underlying trial data submitted to regulators. They also said that principal investigators involved in ticagrelor trials "were unreachable or declined to be interviewed". "The findings raise even deeper questions over the approval and decade long use of the drug," the authors claimed. Dr Victor Serebruany, an expert in cardiovascular pharmacology at Johns Hopkins University in Maryland, who has been critical of the drug for over a decade said: "It's been obvious for years that there is something wrong with the data. "That the FDA's leadership could look past all these problems- on top of the many problems their own reviewers identified and are now being discovered by The BMJ - is unconscionable. "We all need to know how and why that happened. "If doctors had known what happened in these trials, they would never have started using ticagrelor." But a spokesperson for the Sinai Center for Thrombosis Research and Drug Development, which Dr Gurbel leads, told MailOnline: "Any allegations of any research misconduct in the two studies are baseless and erroneous." Sun Health has also contacted Circulation for comment. The journal did not respond to the BMJ. How to reduce your risk of heart attacks and stroke You can reduce your risk of heart attack and stroke with many of the same methods. Heart attacks and strokes, although affecting different organs of the body, are both what we call cardiovascular events. Both arise from similar underlying conditions, such as atherosclerosis —a buildup of fatty deposits in the arteries. According to the American Heart Association, the risk factors for heart attacks and strokes are largely the same: high blood pressure, high cholesterol, smoking, obesity, physical inactivity and diabetes. Therefore, addressing these risk factors can simultaneously reduce the risk of both conditions. Here are ways you can prevent the two: Healthy diet More fruit and veg: The DASH, which emphasises fruit, vegetables, whole grains and lean proteins, has been shown to reduce blood pressure and improve heart health. Less fats: Too much saturated and trans fats can raise cholesterol levels and increase the risk of atherosclerosis. Go for healthier fats like those found in olive oil, nuts, and avocados. Limit salt: High salt intake is linked to high blood pressure, a major risk factor for both heart attack and stroke. The NHS recommends no more than 6g of salt per day for adults. Fibre: Foods high in soluble fibre, such as oats and beans, can help lower cholesterol levels. Exercise Walking, running, cycling, swimming - whatever you like, do it! Aerobic exercise can strengthen the heart and improve circulation. The NHS advises at least 150 minutes of moderate-intensity aerobic activity or 75 minutes of vigorous-intensity activity each week. Strength training exercises can help control weight, improve cholesterol levels, and reduce blood pressure. It is recommended twice a week by the NHS. Manage blood pressure Healthy diet and exercise can help keep your blood pressure in check. But it is worth monitoring it yourself after the age of 40, at least, when the NHS invites adults for a check-up every five years. High blood pressure often has no symptoms but significantly increases the risk of heart attack and stroke. Quit smoking One of the best ways to quit smoking is to use resources provided by NHS Smokefree. Support groups, medications, and other tools to help quit smoking such as vapes could be what you need to kick the habit for good - and it's free. Limit booze Excessive alcohol consumption can increase blood pressure and contribute to weight gain, which can snowball and become a heart health risk. The NHS recommends not regularly drinking more than 14 units of alcohol per week.
Medscape
15 hours ago
- Health
- Medscape
BMJ Investigation Increases Concerns About Ticagrelor Trials
An investigation by The BMJ is raising fresh concerns about the clinical studies that supported the approval of the antiplatelet drug ticagrelor (Brilinta, AstraZeneca), almost 15 years after the medication was first approved and as generic versions are set to hit the market. Peter Doshi, PhD, a senior editor at The BMJ , previously reported inconsistencies and omissions in data reporting from the 2009 PLATO study, published in The New England Journal of Medicine , which showed ticagrelor was superior to clopidogrel in treating acute coronary syndrome. Now a follow-up investigation of two supporting studies published in Circulation , ONSET/OFFSET and RESPOND, has revealed primary endpoints were reported inaccurately, data were missing from the submission to the US Food and Drug Administration (FDA), and study centers may not have received adequate training. Doshi said the results of his investigations call into question the drug's approval and suggested that it should be revisited. 'The FDA's approval in 2011 went against the evidence according to its reviewers, and now, my investigations into PLATO, ONSET/OFFSET, and RESPOND, suggest that even the data presented to the FDA and reported in The New England Journal of Medicine and Circulation , is not trustworthy,' he told Medscape Medical News. The investigation identified several problems with data integrity in the two trials. The original primary endpoint results for RESPOND, which aimed to test whether ticagrelor could convert nonresponders to clopidogrel into responders, were statistically nonsignificant ( P = .157) but were subsequently reported in Circulation as significant ( P = .005) because of an undeclared change in its primary endpoint definition. For ONSET/OFFSET, which reported ticagrelor provided faster and greater inhibition of platelets than clopidogrel, the investigators now claim several patients were excluded from the analysis. However, those who remained were identified as the 'intention-to-treat' population, implying all patients were included. Implausible data points were also included in the analysis of the primary endpoint but were first transformed through an unpublished data analysis, Doshi claimed. Doshi also gained access to readouts from some of the platelet function test machines used in the trial. He found more than 60 of 282 readings were not present in the datasets submitted to the FDA, and the levels of platelet activity in those readings were significantly higher than those reported in Circulation . Victor Serebruany, MD, from Johns Hopkins University in Baltimore, and one of the more high-profile critics of ticagrelor, told The BMJ the missing readings show 'there are episodes of skyrocketing rebound and profound platelet inhibition after ticagrelor, making patients prone to thrombosis or bleeding. If doctors had known what happened in these trials, they would never have started using ticagrelor.' The investigation also revealed oddities around the authorship of the publications. One active trial investigator was never identified as a study author, while one author told The BMJ he was not involved in the trial. The BMJ states that AstraZeneca, the journal Circulation , and many of the original investigators either declined to comment on the new claims or were unreachable. Ticagrelor has been under fire since the beginning. The drug failed in its first bid for FDA approval and was the subject of an investigation by the US Department of Justice in 2013 at the urging of Serebruany. That investigation was closed in 2014 with no further action. A review of several major trials of ticagrelor by Eric Bates, MD, professor of internal medicine at the University of Michigan in Ann Arbor, Michigan, and a co-author of the US guidelines that recommend ticagrelor, concluded 'the clinical conventional wisdom and clinical trial guideline support for…ticagrelor compared with clopidogrel may be overemphasized.' Bates is now calling for a review of ticagrelor's recommendation in guidelines, according to the earlier The BMJ report.
India Today
a day ago
- Health
- India Today
Sorry Dad, science says mom is the smart one
When little Aarav, barely four, started solving puzzles meant for eight-year-olds, his family was stunned, except his mother, who smiled knowingly. "He's always been curious, just like I was," she said, brushing off the praise. At first, everyone assumed it was just maternal pride talking. But as it turns out, science might actually agree with living rooms, classrooms, and playgrounds across the world, children display sparks of brilliance that often lead people to wonder: Where did that come from? For years, the answer felt split down the middle. But now, genetic research is beginning to tip the scales pointing, quite strongly, toward mothers as the primary source of inherited intelligence. Studies suggest that when it comes to IQ, mom may have the upper hand in the genetic lottery. Picture credit: freepik advertisementINTELLIGENCE LIVES ON THE X CHROMOSOMEThe theory that intelligence is passed on more significantly from mothers is rooted in genetics. Humans have 23 pairs of chromosomes, and one pair determines sex XX for females and XY for males. Research shows that many intelligence-related genes are located on the X chromosome. Since women carry two X chromosomes, and men only one, the likelihood of a child inheriting these intelligence genes from the mother is statistically GENES AREN'T THE FULL STORYIt's important to note that genetics accounts for only 40-60% of intelligence. The rest comes down to environment, stimulation, education, and emotional support areas where both parents and caregivers play critical roles. "A child's potential is determined by genes, but how far they go depends on the environment they grow up in," says Dr. Meera Rao, a Delhi-based child psychologist. "Nutrition, emotional security, and access to learning are equally critical."NATURE MEETS NURTUREadvertisementInterestingly, mothers often end up playing a more central role not just genetically, but environmentally as well. Numerous psychological studies show that a secure emotional bondDOES BREASTFEEDING MAKE A CHILD INTELLIGENT?Breastfeeding may have a small positive effect on intelligence in children, but this effect largely disappears when you adjust for factors like the mother's IQ, education, and socio-economic status. Journalist Sarah Hall said to the Guardian "Breastfeeding your baby has little or no effect on its intelligence baby's brainpower 'more a matter of IQ AS A STRONG PREDICTORA BMJ study (2006) of over 5,400 children found that maternal IQ was the strongest predictor of a child's IQ. Once maternal IQ was factored in, other variables like breastfeeding or socio-economic status had little impact on cognitive outcomes. Scientific evidence strongly supports that maternal genes, especially those on the X chromosome, have a disproportionately larger role in determining a child's intelligence but environment and parenting still matter both parents matter, science says intelligence is mostly a mom thing. But don't worry, dads, you still get credit for the hairline.
